by Dan Roberts June 2012 Introduction Here is MD Support’s summary of the the past twelve months of significant research and development in the field of macular degeneration. We begin with the field that has been making the most news: pharmacology. _______________________________ PHARMACOLOGY SEP: Infection Risk From Repackaged Avastin The big pharmaceutical news of the [Read More]
News
The Financial Burden of Eye Disease
Ellen Troyer, MT MA Biosyntrx CEO/Chief Research Officer May 11, 2012 The National Eye Institute (NEI) estimates that the current annual cost of vision impairment and degenerative eye disease to the United States private and public sector exceeds $68 billion. And this number does not fully quantify the impact of lost productivity, diminished quality of [Read More]
IL-18 Can Prevent Inflammation in the Retina
by Dan Roberts Updated April 2014 A new finding by researchers at Trinity College Dublin may lead to another treatment for wet AMD. Inflammation in the retina results from blood vessel development, and the natural component named IL-18 has been found to keep the process under control. By injecting the chemical into the eye, or [Read More]
What Is Macular Degeneration?
by Dan Roberts (Updated 9/12/2023) Audio/visual presentations on all related subjects Recommended books: The First Year: Age-Related Macular Degeneration: An Essential Guide for the Newly Diagnosed by Daniel L. Roberts Macular Degeneration: The Complete Guide to Saving and Maximizing Your Sight by Lylas Mogk, M.D. and Marja Mogk, Ph.D. Definition Age-related macular degeneration (AMD) is [Read More]
New Radiation Treatment for Wet AMD
by Dan Roberts [It was reported on 2/9/12 that Phase III of this study did not meet it’s primary endpoint at 2 years. The information in this article describes the progress up to that point.] NeoVista, Inc. announced on June 17, 2007 the official commencement of the CABERNET (Cnv secondary to Amd treated with BEta [Read More]